CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity

被引:91
作者
Beeler, A. [1 ]
Zaccaria, L. [1 ]
Kawabata, T. [2 ]
Gerber, B. O. [1 ]
Pichler, W. J. [1 ]
机构
[1] Inselspital Bern, Clin Rheumatol & Clin Immunol Allergol, Div Allergol, CH-3010 Bern, Switzerland
[2] Pfizer Inc, Drug Safety Res & Dev, Groton, CT 06340 USA
关键词
CD69; upregulation; drug hypersensitivity; in vitro diagnosis; lymphocyte transformation test; T cells;
D O I
10.1111/j.1398-9995.2007.01516.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: T cells play a key role in delayed-type drug hypersensitivity reactions. Their reactivity can be assessed by their proliferation in response to the drug in the lymphocyte transformation test (LTT). However, the LTT imposes limitations in terms of practicability, and an alternative method that is easier to implement than the LTT would be desirable. Methods: Four months to 12 years after acute drug hypersensitivity reactions, CD69 upregulation on T cells of 15 patients and five healthy controls was analyzed by flow cytometry. Results: All 15 LTT-positive patients showed a significant increase of CD69 expression on T cells after 48 h of drug-stimulation exclusively with the drugs incriminated in drug-hypersensitivities. A stimulation index of 2 as cut-off value allowed discrimination between nonreactive and reactive T cells in LTT and CD69 upregulation. T cells (0.5-3%) showed CD69 up-regulation. The reactive cell population consisted of a minority of truly drug reactive T cells secreting cytokines and a higher number of bystander T cells activated by IL-2 and possibly other cytokines. Conclusions: CD69 upregulation was observed after 2 days in all patients with a positive LTT after 6 days, thus appearing to be a promising tool to identify drug-reactive T cells in the peripheral blood of patients with drug-hypersensitivity reactions.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 31 条
[1]   Task Force Report: Future research needs for the prevention and management of immune-mediated drug hypersensitivity reactions [J].
Adkinson, NF ;
Essayan, D ;
Gruchalla, R ;
Haggerty, H ;
Kawabata, T ;
Sandler, JD ;
Updyke, L ;
Shear, NH ;
Wierda, D .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (03) :S461-S478
[2]   Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions [J].
Barbaud, A ;
Gonçalo, M ;
Bruynzeel, D ;
Bircher, A .
CONTACT DERMATITIS, 2001, 45 (06) :321-328
[3]  
BARNA BP, 1980, AM SOC CLIN PATHOL, P172
[4]   Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions [J].
Beeler, A ;
Engler, O ;
Gerber, BO ;
Pichler, WJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) :455-462
[5]  
Beeler Andreas, 2006, Expert Rev Clin Immunol, V2, P887, DOI 10.1586/1744666X.2.6.887
[6]  
BRANDER C, 1995, J IMMUNOL, V155, P2670
[7]   T-cell involvement in drug-induced acute generalized exanthematous pustulosis [J].
Britschgi, M ;
Steiner, UC ;
Schmid, S ;
Depta, JPH ;
Senti, G ;
Bircher, A ;
Burkhart, C ;
Yawalkar, N ;
Pichler, WJ .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (11) :1433-1441
[8]   In vitro allergy diagnosis:: should we follow the flow? [J].
Ebo, DG ;
Hagendorens, MM ;
Bridts, CH ;
Schuerwegh, AJ ;
De Clerck, LS ;
Stevens, WJ .
CLINICAL AND EXPERIMENTAL ALLERGY, 2004, 34 (03) :332-339
[9]   THE DISCRIMINATION BETWEEN NICKEL-SENSITIVE AND NON-NICKEL-SENSITIVE SUBJECTS BY AN INVITRO LYMPHOCYTE-TRANSFORMATION TEST [J].
EVERNESS, KM ;
GAWKRODGER, DJ ;
BOTHAM, PA ;
HUNTER, JAA .
BRITISH JOURNAL OF DERMATOLOGY, 1990, 122 (03) :293-298
[10]   T cell involvement in cutaneous drug eruptions [J].
Hari, Y ;
Frutig-Schnyder, K ;
Hurni, M ;
Yawalkar, N ;
Zanni, MP ;
Schnyder, B ;
Kappeler, A ;
Von Greyerz, S ;
Braathen, LR ;
Pichler, WJ .
CLINICAL AND EXPERIMENTAL ALLERGY, 2001, 31 (09) :1398-1408